KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax
The findings establish KRT13 as a critical contributor to pancreatic cancer progression, via the PI3K/AKT–PPARG regulatory axis, and underscore the potential of KRT13 as a prognostic biomarker and a candidate therapeutic target.